RICHARD H. SCHELLER - 04 Aug 2021 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Title: Chairman of Research and Development, Director
Signature
/s/ Yi Ching Yau, Attorney-in-Fact
Issuer symbol
BBIO
Transactions as of
04 Aug 2021
Net transactions value
-$499,108
Form type
4
Filing time
06 Aug 2021, 18:08:27 UTC
Previous filing
09 Aug 2021
Next filing
14 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Options Exercise $234,209 +13,777 +30% $17.00 59,637 04 Aug 2021 Direct
transaction BBIO Common Stock Sale $733,317 -13,777 -23% $53.23 45,860 04 Aug 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Stock Option (Right to Buy) Options Exercise $0 -13,777 -26% $0.000000 39,611 04 Aug 2021 Common Stock 13,777 $17.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the weighted average sale price of the shares sold from $52.839 to $53.68 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in this footnote.
F2 The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such date.

Remarks:

Title: Chairman of Research and Development